Skip to main content
Journal cover image

Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.

Publication ,  Journal Article
Castillo, RC; Arango-Jaramillo, S; John, R; Weinhold, K; Kanki, P; Carruth, L; Schwartz, DH
Published in: J Infect Dis
March 2000

An in vitro assay developed as a correlate of vaccine-induced protection from human immunodeficiency virus (HIV) was validated in populations with relative resistance to HIV-1 as well as in HIV vaccine recipients. Cultures of peripheral blood mononuclear cells (PBMC) were challenged with 10 TCID50 of HIV-1MN or HIV-1BaL, titered in PBMC from normal controls (n=57). PBMC from HIV-1-infected persons with low viremia (n=17), exposed uninfected persons (n=23), and HIV-2-infected Senegalese prostitutes (n=9) were significantly resistant to HIV-1BaL and/or HIV-1MN (P<.001). Among 34 HIV vaccine recipients of live canarypox vector expressing multiple HIV-1 gene products with or without rgp120 booster, PBMC from postvaccination samples were significantly resistant to both strains (P<.001), and cytotoxic T lymphocyte precursor-positive samples were significantly more resistant than were precursor-negative samples (P<.03). This is the first evidence of the induction by vaccination of a validated correlate of protection. This assay should serve as a useful criterion for assessing experimental HIV vaccines before phase III efficacy trials.

Duke Scholars

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

March 2000

Volume

181

Issue

3

Start / End Page

897 / 903

Location

United States

Related Subject Headings

  • Viremia
  • T-Lymphocytes, Cytotoxic
  • Microbiology
  • Lymphocyte Activation
  • Humans
  • HIV-1
  • AIDS Vaccines
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 31 Biological sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Castillo, R. C., Arango-Jaramillo, S., John, R., Weinhold, K., Kanki, P., Carruth, L., & Schwartz, D. H. (2000). Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. J Infect Dis, 181(3), 897–903. https://doi.org/10.1086/315300
Castillo, R. C., S. Arango-Jaramillo, R. John, K. Weinhold, P. Kanki, L. Carruth, and D. H. Schwartz. “Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.J Infect Dis 181, no. 3 (March 2000): 897–903. https://doi.org/10.1086/315300.
Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, et al. Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. J Infect Dis. 2000 Mar;181(3):897–903.
Castillo, R. C., et al. “Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity.J Infect Dis, vol. 181, no. 3, Mar. 2000, pp. 897–903. Pubmed, doi:10.1086/315300.
Castillo RC, Arango-Jaramillo S, John R, Weinhold K, Kanki P, Carruth L, Schwartz DH. Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. J Infect Dis. 2000 Mar;181(3):897–903.
Journal cover image

Published In

J Infect Dis

DOI

ISSN

0022-1899

Publication Date

March 2000

Volume

181

Issue

3

Start / End Page

897 / 903

Location

United States

Related Subject Headings

  • Viremia
  • T-Lymphocytes, Cytotoxic
  • Microbiology
  • Lymphocyte Activation
  • Humans
  • HIV-1
  • AIDS Vaccines
  • 42 Health sciences
  • 32 Biomedical and clinical sciences
  • 31 Biological sciences